Mathias Schmidt
Directeur/Bestuurslid bij JCR PHARMACEUTICALS CO., LTD.
Profiel
Mathias Schmidt is currently the Chief Executive Officer & Director at ArmaGen, Inc. and MD, Head-Clinical & Business Development at JCR Pharmaceuticals Co., Ltd.
He is also the President & Chief Executive Officer at JCR USA, Inc. Dr. Schmidt holds a doctorate degree from the University of Freiburg and a graduate degree from Universität Stuttgart.
Actieve functies van Mathias Schmidt
| Bedrijven | Functie | Begin |
|---|---|---|
| JCR PHARMACEUTICALS CO., LTD. | Directeur/Bestuurslid | 01-06-2020 |
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Algemeen Directeur | - |
| JCR USA, Inc. | Algemeen Directeur | - |
Opleiding van Mathias Schmidt
| University of Freiburg | Doctorate Degree |
| Universität Stuttgart | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| JCR PHARMACEUTICALS CO., LTD. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
| JCR USA, Inc. |
